长期使用FK506(他克莫斯)治疗全身型重症肌无力

长期使用FK506(他克莫斯)治疗全身型重症肌无力Konishi T.;Yoshiyama Y.;Takomori M.;Saido T.;王晓琳
【期刊名称】《世界核心医学期刊文摘：神经病学分册》
【年(卷),期】2005(000)007
【摘要】Efficacy and safety of long term use of FK506 (2-4.5 mg/ day)for a maximum of two years were evaluated in 12 patients with generalised myasthenia gravis (MG) . At the end of the study,eight patients (67%) showed improvement in either MG score or Activities in Daily Living score, and prednisolone dosage could be redu ced in seven patients (58%), with a mean reduction ratio of 37%. Long term use of FK506 for MG can be more effective than short term administration, with no s erious side effects.
【总页数】1页(P32-32)
【作者】Konishi T.;Yoshiyama Y.;Takomori M.;Saido T.;王晓琳
【作者单位】Department of Neurology Utano National Hospital;8 Ondoyama-cha Narutaki Kyoto 616-8255 Japan Dr.
【正文语种】中文
【中图分类】R746.1
【相关文献】
1.小剂量他克莫司添加治疗老年难治性全身型重症肌无力的疗效及对外周血相关细胞的影响 [J], 贾东佩
2.小剂量他克莫司治疗难治性全身型重症肌无力的初步评价 [J], 林婧;李荣;张旻;李悦;陈博;卜碧涛
3.评价他克莫司治疗全身型重症肌无力（MG）的疗效及不良反应 [J], 孙睿
4.他克莫司治疗全身型重症肌无力的有效性及安全性评价 [J], LIANG Yi;ZHAO Lina;LIU Xiaoman
5.他克莫司对难治性全身型重症肌无力的临床疗效观察 [J], 王齐
因版权原因，仅展示原文概要，查看原文内容请购买。